Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P62633

UPID:
CNBP_HUMAN

ALTERNATIVE NAMES:
Cellular nucleic acid-binding protein; Zinc finger protein 9

ALTERNATIVE UPACC:
P62633; A8K7V4; B2RAV9; B4DP17; D3DNB9; D3DNC0; D3DNC1; E9PDR7; P20694; Q4JGY0; Q4JGY1; Q5QJR0; Q5U0E9; Q6PJI7; Q96NV3

BACKGROUND:
The CCHC-type zinc finger nucleic acid binding protein, with alternative names Cellular nucleic acid-binding protein and Zinc finger protein 9, is essential for cellular function. It binds to single-stranded DNA and RNA, playing a role in transcriptional repression and facilitating translation by preventing G-quadruplex structure formation in mRNAs.

THERAPEUTIC SIGNIFICANCE:
This protein's mutation is implicated in Dystrophia myotonica 2, characterized by muscle weakness, myotonia, and other systemic symptoms. Exploring the protein's function offers a pathway to developing targeted treatments for this complex disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.